As­traZeneca lines up a $20M in­stall­ment plan to launch a new on­col­o­gy col­lab­o­ra­tion with mi­cro­bio­me play­er Seres

As­traZeneca has set up a re­search deal with Seres Ther­a­peu­tics, agree­ing to pay the biotech $20 mil­lion in in­stall­ment pay­ments for their col­lab­o­ra­tion on ex­plor­ing how the gut can in­flu­ence the ef­fi­ca­cy of im­muno-on­col­o­gy drugs like their PD-L1 Imfinzi.

The phar­ma gi­ant — which hasn’t been do­ing a lot of ear­ly-stage re­search col­lab­o­ra­tions like this — is al­so hand­ing over some re­search sub­si­dies to cov­er the cost of the work at the Cam­bridge, MA-based biotech $MCRB.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER